Amylin, Eli Lilly receive European approval for expanded use of BYETTA
The approval was based on a double-blind trial, in which BYETTA 10 micrograms or placebo was added to existing insulin glargine therapy, which was titrated to achieve target
Kyowa Kirin subsidiary Kyowa Kirin EMEA has received approval from the European Commission (EC) to expand the use of Crysvita (burosumab) for treating X-linked hypophosphataemia (XLH) in infants aged one month to one year across the EU and European Economic Area.
The company specializes in the process, development and manufacture of active pharmaceutical ingredients, nutraceuticals, natural extracts, enzymes and specialty polymers. Bio-gen Extracts marketing director Saif Mehkri told Pharmabiz